Tenofovir News and Research

RSS
TDF alone may be sufficient maintenance in chronic HBV patients

TDF alone may be sufficient maintenance in chronic HBV patients

Meta-analysis sheds light on effectiveness of chronic HBV treatments

Meta-analysis sheds light on effectiveness of chronic HBV treatments

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

TDF switch effective in Asian chronic HBV patients

TDF switch effective in Asian chronic HBV patients

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

Kidney damage unlikely with TDF monotherapy in chronic HBV patients

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Patients with adefovir-resistant HBV benefit from TDF monotherapy

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

No effect of baseline cirrhosis on long-term TDF treatment outcomes

No effect of baseline cirrhosis on long-term TDF treatment outcomes

US health care providers reluctant to prescribe HIV prevention plan

US health care providers reluctant to prescribe HIV prevention plan

Long-term entecavir, TDF effective in chronic HBV in real-world setting

Long-term entecavir, TDF effective in chronic HBV in real-world setting

HBV genotype C HBeAg seroconversion rate ‘negligible’

HBV genotype C HBeAg seroconversion rate ‘negligible’

WHO releases first-ever guidance for chronic hepatitis B treatment

WHO releases first-ever guidance for chronic hepatitis B treatment

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Long-term TDF therapy offers sustained HBV suppression without resistance

Long-term TDF therapy offers sustained HBV suppression without resistance

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial